Skip to main content
    M

    Minerva Neurosciences Inc (NERV)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.20
    -0.10 (-4.35%)

    Market Cap: $114.62M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Minerva Neurosciences Inc (NERV) Financials: Revenue, Profit and Cash Flow

    Updated Nov 6, 2026. Financial statements from company filings, amounts in US dollars.

    Minerva Neurosciences reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$293.42M, operating cash flow was -$13.51M and free cash flow was -$13.51M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of $100.75M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $15.10M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0-100.0%N/AN/AN/A
    Dec 2020$41.18MN/A100.0%4.5%4.7%
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the company posted a net loss after a profit the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$0$0$0$0$0$41.18M$0$0$0$0
    Gross profit$0$0$0$0$0$41.18M$0$0$0$0
    Research and development$5.76M$11.90M$12.71M$14.65M$32.04M$22.04M$58.12M$34.89M$30.26M$20.44M
    Operating income-$15.10M-$21.85M-$23.12M-$25.23M-$45.37M$1.85M-$75.87M-$51.73M-$41.17M-$30.19M
    Net income-$293.42M$1.44M-$30.01M-$32.11M-$49.91M$1.94M-$72.18M-$50.17M-$31.52M-$31.05M
    EBITDAN/A$4.75M-$23.09MN/A-$45.30M$1.87M-$74.97MN/AN/A-$29.75M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$42.22K$0$0$0$0
    Gross profit$0$0$0-$1.36K$0$0$0$21.11K$0$0$0-$7.75K
    Operating income-$9.43M-$10.64M-$16.67M-$4.98M-$2.84M-$3.37M-$3.90M-$4.52M-$4.37M-$6.28M-$6.68M-$7.17M
    Net income$100.75M$17.47M-$125.40M-$283.67M-$2.74M-$3.26M-$3.75M-$4.27M$22.51M-$8.23M-$8.57M-$9.02M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents of $82.30M were 84.0% of total assets of $97.97M, against total liabilities of $233.76M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$97.97M$37.14M$56.90M$55.09M$77.12M$57.63M$77.50M$139.14M$183.70M$132.94M
    Current assets$83.10M$22.27M$42.00M$40.16M$62.20M$27.44M$47.14M$90.02M$129.54M$83.86M
    Cash and equivalents$82.30M$21.36M$40.91M$36.09M$60.76M$25.36M$21.41M$50.23M$26.05M$82.98M
    Total liabilities$233.76M$62.84M$85.36M$75.11M$69.15M$4.96M$49.72M$48.87M$52.10M$26.96M
    Short-term debtN/AN/AN/AN/AN/A$111.23K$172.90K$41.18B$3.96M$4.85M
    Long-term debtN/AN/AN/AN/AN/AN/AN/AN/A$0$3.84M
    Shareholder equity-$140.75M-$25.69M-$28.46M-$20.02M$7.98M$52.66M$27.78M$90.26M$131.60M$105.98M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$98.28M$95.09M$94.03M$97.97M$28.09M$30.42M$32.80M$37.14M$42.81M$46.29M$50.51M$56.90B
    Total liabilities$184.06M$296.65M$343.08M$238.72M$62.67M$62.53M$61.95M$62.84M$64.48M$90.78M$87.10M$85.36B
    Cash and equivalents$20.22M$24.65M$32.66M$82.30M$12.29M$15.25M$17.29M$21.36M$26.53M$30.88M$34.82M$40.91B
    Shareholder equity-$97.52M-$213.30M-$254.01M-$140.75M-$34.58M-$32.11M-$29.15M-$25.69M-$21.67M-$44.49M-$36.59M-$28.46B
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$13.51M-$19.55M-$14.78M-$24.65M-$24.60M-$33.82M-$43.43M-$41.94M$3.09M-$25.69M
    Capital expenditures$0$0$0$16.33K$0$16.33K$3$0$52.40K$0
    Free cash flow-$13.51M-$19.55M-$14.78M-$24.66M-$24.60M-$33.84M-$43.43M-$41.94M$3.04M-$25.69M
    Dividends paidN/AN/AN/AN/AN/AN/AN/AN/A$10.49M$0
    Share repurchases$5.39M$0$396.29K$0N/A$455.67K$0N/A$2.94M$3.83M
    Investing cash flow$0$0$0-$16.33K$0$24.53M$14.08M$69.49M-$107.19M$17.82M
    Financing cash flow$74.45M$0$19.60M-$5$60.00M$13.24M$525.00K-$3.34M$47.17M$76.57M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$8.15M-$13.34M-$5.43M-$4.48M-$2.92M-$2.04M-$4.07M-$5.17M-$4.35M-$3.94M-$6.09M-$5.99M
    Capital expendituresN/AN/A$0$0$2$2$0$0$0$0$0$0
    Free cash flowN/AN/A-$5.43M-$4.48M-$2.92M-$2.04M-$4.07M-$5.17M-$4.35M-$3.94M-$6.09M-$5.99M
    Last 12 quarters

    Frequently Asked Questions About NERV

    What is Minerva Neurosciences' annual revenue?

    Minerva Neurosciences reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Minerva Neurosciences profitable?

    No. Minerva Neurosciences reported net income of -$293.42M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does NERV generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$13.51M minus capital expenditures of $0 produced free cash flow of -$13.51M.

    How much debt does Minerva Neurosciences have?

    The balance sheet dated Dec 31, 2025 reported cash and equivalents of $82.30M.